Key Points
- CEO August Troendle sold 458 Medpace shares at an average price of $600.39, generating approximately $274,979. He retains 603,978 shares, so the transaction reduced his ownership by just 0.08%.
- Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 versus the $3.98 consensus and revenue of $707.33 million. Revenue increased 17.2% year over year, and management issued fiscal 2026 EPS guidance of $17.25–$17.95.
- Analysts maintain a broadly neutral view, with a consensus “Hold” rating and $584.18 average price target. The stock opened at $578.50, while institutional investors own 77.98% of shares.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 458 shares of Medpace stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $600.39, for a total transaction of $274,978.62. Following the sale, the chief executive officer owned 603,978 shares in the company, valued at approximately $362,622,351.42. This trade represents a 0.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Medpace Stock Down 0.6%
NASDAQ MEDP opened at $578.50 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock has a market cap of $16.15 billion, a P/E ratio of 33.91, a PEG ratio of 2.60 and a beta of 1.15. The company's 50-day simple moving average is $536.23 and its 200 day simple moving average is $492.35.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Institutional Trading of Medpace
Several large investors have recently made changes to their positions in the business. Johnson Financial Group Inc. acquired a new stake in shares of Medpace in the second quarter valued at $27,000. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares in the last quarter. Elyxium Wealth LLC acquired a new position in Medpace during the 4th quarter worth about $30,000. Jones Financial Companies Lllp bought a new stake in Medpace during the 2nd quarter worth about $30,000. Finally, Allied Private Wealth LLC bought a new stake in Medpace during the 2nd quarter worth about $31,000. Institutional investors own 77.98% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently commented on MEDP. Truist Financial raised their target price on Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. TD Cowen increased their price objective on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Royal Bank Of Canada boosted their target price on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Finally, BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus price target of $584.18.
Read Our Latest Analysis on MEDP
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
